Skip Nav Destination
Issues
1 February 2015
-
Cover Image
Cover Image
Slowly proliferating cancer cells can be hard to eradicate with currently available drugs, difficult to detect, and are thought to be a cause of late disease relapse. The Rapid Impact study within the current issue used confocal immunofluorescence microscopy to identify an MCF7 breast cancer cell dividing asymmetrically to produce a slowly proliferating daughter cell. The cover images show stains for H3K9me2 (green), phospho-AKT1-S473 (red), tubulin (yellow), and all three merged. See the Rapid Impact article by Dey-Guha, Alves and colleagues (beginning on page 223) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1541-7786
EISSN 1557-3125
Molecular Cancer Research
Table of Contents
Highlights
Review
Rapid Impact
Cell Cycle and Senescence
Global Increase of p16INK4a in APC-Deficient Mouse Liver Drives Clonal Growth of p16INK4a-Negative Tumors
Elke Ueberham; Pia Glöckner; Claudia Göhler; Beate K. Straub; Daniel Teupser; Kai Schönig; Albert Braeuning; Anne Kathrin Höhn; Boris Jerchow; Walter Birchmeier; Frank Gaunitz; Thomas Arendt; Owen Sansom; Rolf Gebhardt; Uwe Ueberham
Cell Death and Survival
Chromatin, Gene, and RNA Regulation
Author Choice
WHSC1 Promotes Oncogenesis through Regulation of NIMA-Related Kinase-7 in Squamous Cell Carcinoma of the Head and Neck
Vassiliki Saloura; Hyun-Soo Cho; Kazuma Kiyotani; Houda Alachkar; Zhixiang Zuo; Makoto Nakakido; Tatsuhiko Tsunoda; Tanguy Seiwert; Mark Lingen; Jonathan Licht; Yusuke Nakamura; Ryuji Hamamoto
DNA Damage and Repair
Genomics
Oncogenes and Tumor Suppressors
Signal Transduction
Journal Archive
Molecular Cancer Research
(2002-Present; volumes 1-current)Published monthly since November, 2002.
(ISSN 0008-5472)
Cell Growth & Differentiation
(1990-2002; volumes 1-13)Published monthly 1990- September, 2002.
(ISSN 1044-9523)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.